title: Preserving cardiac function in the hypertensive patient: why renal parameters hold the key.
abstract: The relationship between cardiovascular and renal pathologies is well recognized in advanced nephropathy and heart failure, but in early disease it has received less attention. Consequently, microalbuminuria screening and interventions that treat early nephropathy remain under-utilized cardioprotective strategies in the hypertensive patient. Agents that delay the progression of renal disease are likely to be cardioprotective by lessening the systemic consequences of renal dysfunction and may have additional cardioprotective effects by exerting beneficial effects on endothelia elsewhere in the body and within the heart. A critical driving factor within both renal and wider cardiovascular pathologies is overactivation of the renin-angiotensin-aldosterone system (RAAS). Accordingly, RAAS-directed antihypertensive agents including both angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) have been demonstrated to have renoprotective effects. In major prospective trials, two ARBs, losartan and irbesartan, have been demonstrated to be renoprotective in patients with frank proteinuria, and one ARB, irbesartan, has been shown to have renoprotective properties in patients with microalbuminuria. For patients with incipient or frank renal dysfunction, an aggressive RAAS-based approach to hypertension management, combining potent blood pressure control with proven renoprotection, may therefore constitute a key component of therapy targeted towards long-term cardioprotection.
authors: Cardiac Care Unit, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France. gilles.montalescot@psl.ap-hop-paris.fr
authors: Gilles
authors: G
authors: Montalescot
authors: Jean-Philippe
authors: JP
authors: Collet
mesh_terms: D000419:Albuminuria / Q000175:diagnosis / Q000209:etiology; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006331:Heart Diseases / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000517:prevention & control; D007674:Kidney Diseases / Q000517:prevention & control*; D011379:Prognosis; D012084:Renin-Angiotensin System / Q000187:drug effects
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors